Author Topic: What are you buying today?  (Read 1781696 times)

Orchard

  • Full Member
  • ***
  • Posts: 102
Re: What are you buying today?
« Reply #5460 on: July 02, 2020, 09:16:36 AM »
1) CEQP's contracts with CHK were changed in 2017 and I don't think CHK will be able to reject these in Ch11
It's nice to see that you got to set your own terms for the bankruptcy while everyone else has to play according to the country's laws.


lnofeisone

  • Jr. Member
  • **
  • Posts: 96
Re: What are you buying today?
« Reply #5461 on: July 02, 2020, 02:05:36 PM »
1) CEQP's contracts with CHK were changed in 2017 and I don't think CHK will be able to reject these in Ch11
It's nice to see that you got to set your own terms for the bankruptcy while everyone else has to play according to the country's laws.

Orchard - I think this is a snarky comment but I'm going to assume positive intent here and ask. What part of my statement shows that I set my own terms while everyone else has to play according to country's laws? CEQP has a MRG contract for CHK. There is hardly a contract that's more favorable to CHK (or anyone really) so why would the court reject it?

benchmark

  • Sr. Member
  • ****
  • Posts: 337
Re: What are you buying today?
« Reply #5462 on: July 03, 2020, 06:58:35 PM »
What's the PDLI liquidation play? simple google didn't yield anything

https://www.sec.gov/Archives/edgar/data/882104/000088210420000057/pdli-2020def14adoc.htm#se100117011f048748132db3631831519

You got some reading to do.  Cop a squint at the sections entitled:
"general information about the dissolution and plan of dissolution."
"Proposal #3"

wabuffo

Thank you Wabuffo.

I have some questions regarding the timeline of this, especially with the long tail mentioned in the doc:


principal and interest payments due under a credit agreement entered into by the Company, as a lender, with CareView Communications, Inc., the recoverable amount of which is expected to be substantially less than the principal and interest payable;

amounts received in connection with our agreement with a counterparty pursuant to which we sold the remaining assets of DFM, LLC, to which we are entitled to a single-digit percentage of any net final award in connection with its monetization process using certain intangible assets included in the sale;

amounts received from a royalty based on a “know-how” license for technology provided in the design of solanezumab, an Eli Lilly-licensed humanized monoclonal antibody being tested in a study of older individuals who may be at risk of memory loss and cognitive decline due to Alzheimer’s disease. The 2% royalty on net sales is payable for 12.5 years after the product’s first commercial sale, and is currently in ongoing clinical studies with Phase 3 testing results expected in July of 2022;


If they distribute the cash say by end of 2020,  but receives royalty payment later. Is the shareholders supposed to track this themselves for tax purpose? How are these treated?

Overall, what's your eval of the potential payment and timeline?

thanks much.